Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03561883 · ClinicalTrials.gov registry record · Phase 3
Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
A Phase 3 study, sponsored by Ironwood Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 609
- Enrollment target
NCT03561883 is a Phase 3 study that has completed, run by Ironwood Pharmaceuticals. The registered enrollment target is 609 participants.
The verdict
NCT03561883, a Phase 3 study, has completed, sponsored by Ironwood Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 609 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and efficacy of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation, while receiving once-daily (QD), standard dose PPIs.
Interventions
- DRUG placebo
- DRUG IW-3718
- DRUG Standard-dose PPIs QD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 609 participants |
| Start Date | 2018-09-06 |
| Est. Completion | 2020-11-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03561883
The ClinicalTrials.gov registry entry for NCT03561883 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 609 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ironwood Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT03561883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03561883 about?
NCT03561883 is a clinical study titled "Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)". The objective of this study is to evaluate the safety and efficacy of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation, while receiving once-daily (QD), standard dose PPIs.
What is the current status of trial NCT03561883?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 609 participants. The study started on 2018-09-06. Estimated completion is 2020-11-06.
What interventions are being tested in trial NCT03561883?
The interventions under investigation include: placebo (DRUG), IW-3718 (DRUG), Standard-dose PPIs QD (DRUG).
Who is sponsoring clinical trial NCT03561883?
This trial is sponsored by Ironwood Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.